Algernon Health to open brain PET scanning clinic

Executive Summary

• Algernon Health Inc. is launching its first brain-dedicated PET scanning clinic in the U.S. at the HCA Florida University Medical Office Building in Davie, Florida, marking a strategic entry into the neuroimaging sector.
• The clinic will deploy the FDA-cleared CareMiBrain stand-alone PET scanner to detect Alzheimer’s disease, dementia, epilepsy, and other neurological conditions, capitalizing on a growing market driven by new FDA-approved AD therapies that require beta-amyloid imaging.
• The company has secured a five-year lease, finalized a non-dilutive equipment financing agreement valued at over $4 million for four initial scanners, and outlined a multi-clinic expansion strategy across the United States.

Key Details

• Lease & Location: Algernon USA LLC signed a five-year lease with a five-year renewal option for the inaugural clinic at 7630 SW 34th Manor, Davie, FL (HCA Florida University Medical Office Building).
• Technology & Equipment: Utilizes the U.S. FDA-cleared CareMiBrain system (developed by Oncovision, exclusively marketed in the U.S. by Catalyst MedTech). It is a stand-alone PET scanner without an integrated CT component, reducing patient radiation exposure by ~25% while delivering <1.6mm spatial resolution.
• Financing Structure: Non-dilutive deal with Catalyst MedTech valued at over $4 million for four CareMiBrain systems to be installed in the first four planned clinics. Includes an agreement to acquire six additional systems for future U.S. clinics at an adjusted cost basis.
• Target Indications & Reimbursement: Focuses on beta-amyloid plaque detection for Alzheimer’s disease, as well as epilepsy, neuro-oncology, and movement disorders (e.g., Parkinson’s). Beta-amyloid scans are covered by Medicare, Medicaid, and private insurance for patients over 65.
• Market Opportunity & Supply Gap: Driven by FDA-approved monoclonal antibody treatments (Leqembi and Kisunla) that mandate positive beta-amyloid scans. Current U.S. PET/CT supply is insufficient, with 45% of scanners located in hospitals primarily prioritized for cancer and cardiac imaging.
• Target Demographics & Strategy: Clinic serves a 60-mile radius with ~6.4 million residents, including 2.5 million aged 50+. Strategy includes partnerships with neurologists, geriatricians, and primary care physicians for referrals, alongside direct marketing to the over-50 population for early detection education.
• System Specifications: Features continuous monolithic crystal detector technology, ergonomic reclining chair design, ultrafast acquisition times, standard wall outlet power (115-240V), low heat generation, compact footprint (~8x13 ft), and weighs ~660 lbs. Optional integration with SynterMed NeuroQ4 for quantitative brain analysis.
• Next Steps: Company to announce the official clinic opening date, referral acceptance start date, and patient scanning commencement shortly.

Notable Quotes

• "We are very pleased to be opening our first neuroimaging clinic in a brand new suite at the HCA Florida University medical office building," said Christopher J. Moreau, chief executive officer of Algernon. "We look forward to delivering the highest level of care possible to our patients in Florida, as part of a professional health care community that is dedicated to medical excellence."